On May 27, 2026 Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technology, and ImmuXell Biotech, a Shanghai-based clinical-stage cell therapy company, reported their strategic partnership which began in December 2025. The milestone: the first patient has been dosed in an investigator initiated trial (IIT) using ImmuXell’s TCR-T cell therapy manufactured on Ori’s IRO platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The IIT is aiming to evaluate ImmuXell’s TCR-T therapy in patients with solid tumors harboring KRAS G12V mutations, including those with colorectal cancer, pancreatic cancer, and lung cancer — all among the deadliest and most treatment-resistant cancers. This is a proof point that the IRO platform can take a therapy from process development to patient dosing with the speed, quality, and consistency that GMP manufacturing demands.
From platform installation to first patient dosed in four months, the Ori and ImmuXell teams working together have rapidly adapted and optimized ImmuXell’s proprietary manufacturing process on IRO, demonstrating the platform’s flexibility without sacrificing safety, efficacy or quality. The partnership includes IRO platform deployment at ImmuXell’s Shanghai facilities, with full scientific and technical support from Ori. The two companies plan to progress the current IIT and file an IND application in China to conduct a Phase 1 clinical trial later in 2026.
Jason C. Foster, CEO, Ori Biotech, said:
"This is the milestone we’ve been building toward for the last 7 years — IRO manufacturing a therapy for a patient who desperately needs it. Our platform was designed to eliminate the tradeoffs that have held back cell therapy: speed vs. quality, scale vs. cost, R&D vs. GMP. This partnership with ImmuXell demonstrates that IRO can deliver on all of them, in one of the world’s most important emerging biopharma markets, in the most intractable cancers, quickly and efficiently. We’re proud to be the manufacturing backbone for ImmuXell’s clinical ambitions, and we see this as the first step in a long and impactful collaboration."
Dr. HongMing Hu, Founder, ImmuXell Biotech, said:
"When you’re developing therapies for cancers with no good treatment options, speed to patients is everything. IRO let us move faster than we thought possible — adapting to our unique process, hitting our CQAs, and outperforming the flask and bag based manufacturing approach we had been using for years in just a few short months. Ori is the kind of partner that makes the impossible feel achievable. We look forward to bringing our TCR-T therapy to more patients in China this year and working together with Ori on our ex-vivo cell therapy pipeline."
This partnership marks Ori’s first collaboration in Asia Pacific and underscores the company’s rapid global momentum. IRO now counts 18 partners worldwide — including the recently announced partnership with AdAlta and Cell Therapies Pty in Australia as well as longstanding US partners Charles River Laboratories, CTMC, ElevateBio, and Kincell Bio, as well as other leading CDMOs and two Tier 1 pharma companies. Since its commercial launch in December 2024, IRO has been adopted across R&D, PD and now clinical settings. Ori expects the first INDs for IRO-manufactured products to be filed in late 2026.
(Press release, ImmuXell Biotech, MAY 27, 2026, View Source [SID1234666130])